Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC

Slides:

Advertisements

Similar presentations

Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R

Advertisements

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung Sai-Hong.

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Sarah J. Gao, BS, Christopher D. Corso, MD, PhD, Elyn H

Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F

Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind,

SC17.02 Lung Cancer in China: Challenges and Perspectives

Adjuvant Chemotherapy for T3 Non–Small Cell Lung Cancer with Additional Tumor Nodules in the Same Lobe Michelle C. Salazar, MD, Joshua E. Rosen, BASc,

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Paul J. Scheel, BS, Traves D. Crabtree, MD, Jennifer M

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base Amy C. Moreno,

Clinical T2N0 Esophageal Cancer: Identifying Pretreatment Characteristics Associated With Pathologic Upstaging and the Potential Role for Induction Therapy

Hedgehog Signaling Pathway and Lung Cancer

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Karin J. C. Sanders, MD, Lizza E. Hendriks, MD, Esther G. C

Brian N. Arnold, MD, Daniel C. Thomas, MD, MPH, Joshua E

Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung Cancer Daniel Morgensztern, MD, Saiama.

Serum Thymidine Kinase 1 Activity in the Prognosis and Monitoring of Chemotherapy in Lung Cancer Patients: A Brief Report Benjamin Nisman, PhD, Hovav.

Prognostic Factors in Completely Resected Node-Negative Lung Adenocarcinoma of 3 cm or Smaller Jung-Jyh Hung, MD, PhD, Yi-Chen Yeh, MD, Yu-Chung Wu,

National Patterns of Care and Outcomes After Combined Modality Therapy for Stage IIIA Non–Small-Cell Lung Cancer Aalok P. Patel, BS, Traves D. Crabtree,

Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R

A Combined Prognostic Serum Interleukin-8 and Interleukin-6 Classifier for Stage 1 Lung Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening.

Adjuvant Chemotherapy Is Associated With Improved Survival in Locally Invasive Node Negative Non-Small Cell Lung Cancer Usman Ahmad, MD, Traves D. Crabtree,

Defining the Ideal Time Interval Between Planned Induction Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer Pamela Samson, MD, MPHS, Traves.

Propensity score–matched analysis of adjuvant chemotherapy for stage I non–small cell lung cancer Yasuhiro Tsutani, MD, PhD, Yoshihiro Miyata, MD, PhD,

The Role of Surgical Resection in Stage IIIA Non-Small Cell Lung Cancer: A Decision and Cost-Effectiveness Analysis Pamela Samson, MD, Aalok Patel, BS,

Quality Measures in Clinical Stage I Non-Small Cell Lung Cancer: Improved Performance Is Associated With Improved Survival Pamela Samson, MD, MPHS, Traves.

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green

Defining Optimal Comorbidity Measures for Patients With Early-Stage Non-small cell lung cancer Treated With Stereotactic Body Radiation Therapy Todd.

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

Treatment Outcomes in Stage I Lung Cancer

Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small.

Maria Q. Baggstrom, MD, Saiama N. Waqar, MD, Ananth K

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Performance Status and Smoking Status Are Independent Favorable Prognostic Factors for Survival in Non-small Cell Lung Cancer: A Comprehensive Analysis.

Should Patient-Rated Performance Status Affect Treatment Decisions in Advanced Lung Cancer? Esther Dajczman, RN, MScA, Goulnar Kasymjanova, MD, PhD,

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Does Lymph Node Metastasis Have a Negative Prognostic Impact in Patients with NSCLC and M1a Disease? Chenyang Dai, MD, Yijiu Ren, MD, Dong Xie, MD, PhD,

Clinical Relevance of Our Multimodality Prognostic Score

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

It’s All in the “Swerve of the Curve”

Predictors of Surgery and Consult with an Oncologist for Adjuvant Chemotherapy in Early Stage NSCLC Patients in Alberta, Canada Marcy Winget, PhD, Jennifer.

A Phase II Study of Irinotecan and Carboplatin in Advanced Non-small Cell Lung Cancer with Pharmacogenomic Analysis: Final Report Giancarlo A. Pillot,

Michael Hsie, MD, Stefania Morbidini-Gaffney, MD, Leslie J

International Thymic Malignancies Interest Group: A Way Forward

Adhering to Quality Measures in Esophagectomy Is Associated With Improved Survival in All Stages of Esophageal Cancer Pamela Samson, MD, MPHS, Varun.

A Phase II Study of Carboplatin, Etoposide, and Exisulind in Patients with Extensive Small Cell Lung Cancer: CALGB 30104 Ramaswamy Govindan, MD, Xiaofei.

Stephen R. Broderick, MD, MPHS, Aalok P. Patel, BS, BA, Traves D

Patterns of care in hilar node-positive (N1) non–small cell lung cancer: A missed treatment opportunity? Matthew J. Bott, MD, Aalok P. Patel, BS, Vivek.

Effects of Delayed Surgical Resection on Short-Term and Long-Term Outcomes in Clinical Stage I Non-Small Cell Lung Cancer Pamela Samson, MD, Aalok Patel,

Surveillance and the second primary lung cancer: Enhancing our understanding beyond Martini and Melamed Melanie P. Subramanian, MD, Varun Puri, MD, MSCI

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Temporal Trends in Long-Term Survival and Cure Rates in Esophageal Cancer: A SEER Database Analysis Attila Dubecz, MD, Isabell Gall, MD, Norbert Solymosi,

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

Population-Based Patterns of Surgical Care for Stage IIIA NSCLC in the Netherlands between 2010 and 2013 Chris Dickhoff, MD, Max Dahele, MBChB., PhD,

Robert Comis, MD, The Passing of a “Lung Man”

Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey.

Node-Negative Non-small Cell Lung Cancer: Pathological Staging and Survival in 1765 Consecutive Cases Benjamin M. Robinson, BSc, MBBS, Catherine Kennedy,

Presentation transcript:

Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC Daniel Morgensztern, MD, Lingling Du, MD, Saiama N. Waqar, MD, Aalok Patel, MD, Pamela Samson, MD, Siddhartha Devarakonda, MD, Feng Gao, PhD, Cliff G. Robinson, MD, Jeffrey Bradley, MD, Maria Baggstrom, MD, Ashiq Masood, MD, Ramaswamy Govindan, MD, Varun Puri, MD, MSCI Journal of Thoracic Oncology Volume 11, Issue 10, Pages 1729-1735 (October 2016) DOI: 10.1016/j.jtho.2016.05.022 Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Kaplan-Meier survival curves according to tumor size and use of chemotherapy: (A) tumor size 3.1 to 3.9 cm, (B) tumor size 4 to 4.9 cm, (C) tumor size 5 to 5.9 cm, and (D) tumor size 6 to 7 cm. Journal of Thoracic Oncology 2016 11, 1729-1735DOI: (10.1016/j.jtho.2016.05.022) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Kaplan-Meier analysis for propensity score–matched patients with NSCLC with a tumor size of 3.1 to 3.9 cm by adjuvant chemotherapy status. Journal of Thoracic Oncology 2016 11, 1729-1735DOI: (10.1016/j.jtho.2016.05.022) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions